PL3060229T3 - Stabilne, wodne formulacje przeciwciała - Google Patents
Stabilne, wodne formulacje przeciwciałaInfo
- Publication number
- PL3060229T3 PL3060229T3 PL14855343T PL14855343T PL3060229T3 PL 3060229 T3 PL3060229 T3 PL 3060229T3 PL 14855343 T PL14855343 T PL 14855343T PL 14855343 T PL14855343 T PL 14855343T PL 3060229 T3 PL3060229 T3 PL 3060229T3
- Authority
- PL
- Poland
- Prior art keywords
- stable
- antibody formulations
- aqueous antibody
- aqueous
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895143P | 2013-10-24 | 2013-10-24 | |
| EP14855343.1A EP3060229B1 (en) | 2013-10-24 | 2014-10-23 | Stable, aqueous antibody formulations |
| PCT/US2014/061997 WO2015061584A1 (en) | 2013-10-24 | 2014-10-23 | Stable, aqueous antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3060229T3 true PL3060229T3 (pl) | 2021-12-27 |
Family
ID=52993565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14855343T PL3060229T3 (pl) | 2013-10-24 | 2014-10-23 | Stabilne, wodne formulacje przeciwciała |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20150118249A1 (pl) |
| EP (2) | EP3060229B1 (pl) |
| JP (3) | JP6483673B2 (pl) |
| KR (3) | KR20210041101A (pl) |
| CN (4) | CN119971024A (pl) |
| AU (4) | AU2014339984B2 (pl) |
| BR (1) | BR112016008576B1 (pl) |
| CA (1) | CA2926089C (pl) |
| CY (1) | CY1125697T1 (pl) |
| DK (1) | DK3060229T3 (pl) |
| ES (1) | ES2893861T3 (pl) |
| HR (1) | HRP20211371T1 (pl) |
| HU (1) | HUE055919T2 (pl) |
| LT (1) | LT3060229T (pl) |
| MX (2) | MX388893B (pl) |
| PL (1) | PL3060229T3 (pl) |
| PT (1) | PT3060229T (pl) |
| RS (1) | RS62419B1 (pl) |
| RU (2) | RU2763787C2 (pl) |
| SG (2) | SG10201803178UA (pl) |
| SI (1) | SI3060229T1 (pl) |
| SM (1) | SMT202100580T1 (pl) |
| WO (1) | WO2015061584A1 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
| CA2870149A1 (en) * | 2012-05-03 | 2013-11-07 | Medimmune, Llc | Method for analyzing sample components |
| TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| PT3060229T (pt) * | 2013-10-24 | 2021-10-07 | Astrazeneca Ab | Formulações aquosas estáveis de anticorpos |
| JP6728053B2 (ja) | 2014-03-12 | 2020-07-22 | プロセナ バイオサイエンシーズ リミテッド | 抗ｍｃａｍ抗体及び関連する使用方法 |
| CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| WO2017046776A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| EP3383435A4 (en) * | 2015-11-30 | 2019-07-10 | Medimmune, LLC | OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS |
| EP3498263B1 (en) * | 2016-08-10 | 2023-11-29 | Celltrion Inc. | Stable liquid pharmaceutical preparation for anti-influenza virus antibody |
| EP3528787B1 (en) | 2016-10-21 | 2026-01-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| KR20210145187A (ko) * | 2019-03-29 | 2021-12-01 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도 |
| WO2021124793A1 (ja) * | 2019-12-16 | 2021-06-24 | ニプロ株式会社 | 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス |
| CN111024963A (zh) * | 2019-12-27 | 2020-04-17 | 桂林英美特生物技术研究所 | 一种液体稳定、抗冰冻的免疫比浊法载脂蛋白b单试剂 |
| WO2021182874A1 (ko) * | 2020-03-13 | 2021-09-16 | 삼성바이오에피스 주식회사 | 안정성이 증진된 액상 약제학적 조성물 |
| CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业（上海）股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
| IL300182A (en) * | 2020-07-28 | 2023-03-01 | Chugai Pharmaceutical Co Ltd | Preparation of a pre-filled syringe with a needle, supplied with a needle guard and containing a new modified antibody |
| CA3204307A1 (en) * | 2020-12-17 | 2022-06-23 | Astrazeneca Ab | Anti-il5r antibody formulations |
| WO2026027944A1 (en) * | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0428534B1 (en) | 1988-06-14 | 1995-03-29 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ES2178635T3 (es) | 1990-11-09 | 2003-01-01 | Stephen D Gillies | Inmunoconjugados de citoquinas. |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| WO1997010354A1 (fr) * | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine |
| JP4308249B2 (ja) * | 2003-05-26 | 2009-08-05 | ビャク，ウー・イン | 使い捨て式注射器 |
| DE202006001995U1 (de) * | 2006-02-07 | 2006-06-08 | Sarstedt Ag & Co. | Probengefäß zur Aufnahme von kleinen Flüssigkeitsmengen für Analysen |
| US8945564B2 (en) * | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
| CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| HUE026728T2 (en) | 2007-05-14 | 2016-06-28 | Medimmune Llc | A method for reducing eosinophil levels |
| KR20140019035A (ko) * | 2008-09-19 | 2014-02-13 | 에프. 호프만-라 로슈 아게 | 신규한 항체 제형 |
| AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| RU2560701C2 (ru) * | 2009-05-04 | 2015-08-20 | Эббви Байотекнолоджи Лтд. | Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| CN104011073B (zh) * | 2011-10-18 | 2017-08-25 | 科荣生生物科学公司 | 使用氨基酸稳定的依那西普制剂 |
| US20130109807A1 (en) * | 2011-10-26 | 2013-05-02 | Bio-Rad Laboratories, Inc. | Removal of virucidal agents in mixed mode chromatography |
| CN104023748B (zh) * | 2011-10-28 | 2018-03-02 | 诚信生物公司 | 含有氨基酸的蛋白质制剂 |
| KR20140097217A (ko) * | 2011-11-01 | 2014-08-06 | 메디뮨 엘엘씨 | 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법 |
| WO2015023504A1 (en) * | 2013-08-12 | 2015-02-19 | Medlmmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| RS58711B1 (sr) * | 2013-08-12 | 2019-06-28 | Astrazeneca Ab | Postupci za povećanje forsiranog ekspiratornog volumena kod asmatičara korišćenjem benralizumaba |
| PT3060229T (pt) * | 2013-10-24 | 2021-10-07 | Astrazeneca Ab | Formulações aquosas estáveis de anticorpos |
-
2014
- 2014-10-23 PT PT14855343T patent/PT3060229T/pt unknown
- 2014-10-23 WO PCT/US2014/061997 patent/WO2015061584A1/en not_active Ceased
- 2014-10-23 EP EP14855343.1A patent/EP3060229B1/en active Active
- 2014-10-23 SG SG10201803178UA patent/SG10201803178UA/en unknown
- 2014-10-23 HU HUE14855343A patent/HUE055919T2/hu unknown
- 2014-10-23 KR KR1020217009731A patent/KR20210041101A/ko not_active Ceased
- 2014-10-23 CN CN202411964617.5A patent/CN119971024A/zh active Pending
- 2014-10-23 ES ES14855343T patent/ES2893861T3/es active Active
- 2014-10-23 CN CN201480055263.0A patent/CN105611938B/zh active Active
- 2014-10-23 MX MX2016004605A patent/MX388893B/es unknown
- 2014-10-23 KR KR1020167012565A patent/KR102109053B1/ko active Active
- 2014-10-23 HR HRP20211371TT patent/HRP20211371T1/hr unknown
- 2014-10-23 SM SM20210580T patent/SMT202100580T1/it unknown
- 2014-10-23 SG SG11201603206UA patent/SG11201603206UA/en unknown
- 2014-10-23 CN CN202110799711.XA patent/CN113350278B/zh active Active
- 2014-10-23 CN CN202010809794.1A patent/CN112107538A/zh active Pending
- 2014-10-23 AU AU2014339984A patent/AU2014339984B2/en active Active
- 2014-10-23 CA CA2926089A patent/CA2926089C/en active Active
- 2014-10-23 LT LTEPPCT/US2014/061997T patent/LT3060229T/lt unknown
- 2014-10-23 RU RU2016119755A patent/RU2763787C2/ru active
- 2014-10-23 PL PL14855343T patent/PL3060229T3/pl unknown
- 2014-10-23 RS RS20211238A patent/RS62419B1/sr unknown
- 2014-10-23 BR BR112016008576-0A patent/BR112016008576B1/pt active IP Right Grant
- 2014-10-23 SI SI201431876T patent/SI3060229T1/sl unknown
- 2014-10-23 DK DK14855343.1T patent/DK3060229T3/da active
- 2014-10-23 EP EP20207556.0A patent/EP3892288A1/en active Pending
- 2014-10-23 US US14/521,870 patent/US20150118249A1/en not_active Abandoned
- 2014-10-23 KR KR1020207012828A patent/KR102238065B1/ko active Active
- 2014-10-23 JP JP2016525876A patent/JP6483673B2/ja active Active
- 2014-10-23 RU RU2021137159A patent/RU2021137159A/ru unknown
-
2016
- 2016-04-11 MX MX2021015825A patent/MX2021015825A/es unknown
-
2019
- 2019-02-14 JP JP2019024364A patent/JP6896781B2/ja active Active
-
2020
- 2020-03-25 US US16/829,659 patent/US20200297855A1/en not_active Abandoned
- 2020-07-09 AU AU2020204608A patent/AU2020204608A1/en not_active Abandoned
-
2021
- 2021-06-09 JP JP2021096239A patent/JP2021152034A/ja active Pending
- 2021-10-19 CY CY20211100902T patent/CY1125697T1/el unknown
-
2022
- 2022-12-23 AU AU2022291595A patent/AU2022291595B2/en active Active
-
2025
- 2025-02-04 US US19/045,166 patent/US20250170245A1/en active Pending
- 2025-09-12 AU AU2025230794A patent/AU2025230794A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3060229T3 (pl) | Stabilne, wodne formulacje przeciwciała | |
| CL2016000680A1 (es) | Formulaciones de anticuerpos anti-pdl1. | |
| FR3006466B3 (fr) | . | |
| EP3065716C0 (en) | FORMULATIONS | |
| ME03442B (me) | Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi | |
| DK3336106T3 (da) | Anti-fcrh5-antistoffer | |
| DK3460054T3 (da) | Histidyl-tRNA-syntetase-Fc-konjugater | |
| DK3708583T3 (da) | Ikke-fucosylerede anti-fgfr2iiib-antistoffer | |
| BR302014001378S1 (pt) | Configuração aplicada em bolsa. | |
| CL2016000077A1 (es) | Azinas herbicidas. | |
| LT3003386T (lt) | Antikūno-vaisto konjugatai | |
| BR112016015105A8 (pt) | conjugados var2csa-droga | |
| DK3068800T3 (da) | FcRn-specifikke antistoffer | |
| DK2975030T3 (da) | Dihydropyridazin-3,5-dion-derivat | |
| DK3055664T3 (da) | Faldlodsdeflektometer. | |
| LT2945641T (lt) | Sacharidai, gauti iš cikloalkinų | |
| DK3065774T3 (da) | Anti-CCL17-antistoffer | |
| FR3001302B1 (fr) | . | |
| HUE058086T2 (hu) | Lassú hatóanyagleadású szilárd készítmények | |
| HUE050917T2 (hu) | Hidrokortizon-tartalmú készítmény | |
| FR3001303B1 (fr) | . | |
| HK40126992A (zh) | 稳定的水性抗体配制品 | |
| HK1227741A1 (zh) | 穩定的含水抗體製劑 | |
| BR302013000239S1 (pt) | Configuração aplicada em tamanco. | |
| TH1501001069A (th) | ตัวกระตุ้น |